5-(2-苯基-1,2,3-三唑基)-3-芳基吡唑啉衍生物的合成及其荧光性能

以2-苯基-1, 2, 3-三唑基-4-甲醛为原料, 与苯乙酮［或取代苯乙酮(1a~1d)］发生羟醛缩合, 生成相应的查尔酮(2a~2d), 再与不同的肼反应, 合成了12种新的5位含2-苯基-1, 2, 3-三唑基的吡唑啉衍生物3a~3d, 4a~4d, 5a~5d. 化合物的结构经元素分析、 IR光谱和1 H NMR谱确认, 并测定了化合物的荧光光谱. 结果显示所合成的目标化合物有荧光, 是一类新型的荧光化合物.     

3-取代胺甲基-5-连三唑基-1,3,4-噁二唑-2-硫酮的合成

2-苯基-1,2,3-三唑-4-甲酰肼(1)在CS_2/KOH作用下环化得到5-(2-本基-1,2,3-连三唑-4-基)-1,3,4-噁二唑-2-硫酮(2),2经Mannich反应合成得到标题化合物3-取代胺甲基-5-(2-本基-1,2,3-连三唑-4-基)-1,3,4-噁二唑-2-硫酮(3)。     

Br?nsted酸催化N1-对甲基苯磺酰基三唑与烯烃加成合成高N2选择性的烷基-1,2,3-三唑

N-取代基-1,2,3-三唑广泛应用于生物科学、材料化学和药物化学领域,近几年来引起了人们很大兴趣. N1-取代基-1,2,3-三唑既可由加热催化,也可通过金属诱导的(铜(Ⅰ)催化的1,4-双取代和钌(Ⅱ)催化的1,5-双取代)1,3偶极子环加成反应制备得到,然而有关N2-取代基-1,2,3-三唑的合成仍未获得太大进展.目前,高N2选择性的N2-芳基和N2-烯丙基-1,2,3-三唑的合成方法是利用大位阻的膦配体配位钯催化偶联反应.2008年,史晓东课题组报道了烷基卤化物与大体积的 C-4和 C-5双取代基的NH-1,2,3-三唑通过亲核反应合成N2-烷基-1,2,3-三唑,但其应用受到底物限制.我们设想N1-烷基-1,2,3-三唑可否由N1-取代1,2,3-三唑合成,由于N1-取代基-1,2,3-三唑制备的研究较多,其合成方法将可很方便地构造N2-烷基-1,2,3-三唑化合物.鉴于此,本文对单取代三唑、未取代三唑与包括乙烯基酯在内的多种烯烃的反应进行了研究.首先,我们用不同取代基的N1-1,2,3-三唑与烯烃在不同的酸催化条件下进行反应,考察了酸效应对反应收率的影响,发现 TsOH做 Br?nsted酸为催化剂时,反应产率最高;而 AuCl3做 Lewis酸为催化剂时反应几乎没有加成产物生成.然后,以 TsOH为催化剂,改变三唑与烯烃的加入比例,发现加入比例为1：6时反应产率最高.当N1取代基是 Ts-时,反应产率最高.催化剂 TsOH的加入量由1当量升至2当量时,反应产率没有明显变化.由此表明,N1-1,2,3-三唑与烯烃的最佳反应条件为：催化剂为 TsOH(1当量),N1-1,2,3-三唑的取代基为 Ts,N1-1,2,3-三唑与烯烃的加入比例为1：6.在确定了最佳反应条件后,考察了三唑类底物的适用性.结果发现, N2/N1产物的比例均很高,说明该反应具有很高的N2选择性.上述研究表明, TsOH酸催化N1-对甲苯磺酰基-1,2,3-三唑与烯烃的加成反应是一种有效合成N2-烷基-1,2,3-三唑的新方法,并通过单晶确定了最终的产物结构.单取代三唑和未取代三唑与包括乙烯基酯在内的多种烯烃反应合成N2-烷基-1,2,3-三唑都有很好的反应效果.本文提供了一种简单有效的合成N2-烷基-1,2,3-三唑的新方法.     

1,3-偶极环加成反应合成1-(取代苄基)-1,2,3-三唑类化合物

利用苄氯和取代苄氯与叠氮化钠的亲核取代反应合成了一系列苯环上带有不同取代基团的苄基叠氮化合物,亲核取代反应速率受苯环上取代基的影响:吸电子基团的存在,可以促使反应更容易进行.合成的叠氮化合物与苯乙炔经1,3-偶极环加成反应得到了相应的取代苄基1,2,3-三唑类化合物,反应条件温和.这些1,2,3-三唑类目标化合物具有对热稳定的优点.用红外、核磁、元素分析、质谱等对合成的叠氮化合物和1,2,3-三唑类化合物的结构进行了表征,重点研究了1,3-环加成反应的规律.加成反应速率取决于叠氮化合物(偶极物)的极性,即与取代基的电负性有关:苯乙炔(亲偶极物)易于与缺电子的叠氮反应,反之亦然.同时在反应过程中观察到空间位阻效应:反应可以生成两种同分异构体,其中4-苯基-1,2,3-三唑是主要产物.     

1-(2′-苯基-1′,2′,3′-三唑-4′-甲酰基)-4-芳基氨基硫脲及其环化产物的合成

以2-苯基-1,2,3-三唑-4甲酰肼为原料合成了几种新的1-(2′-苯基-1′,2′,3′-三唑-4′-甲酰基)-4芳基氨基硫脲,在不同条件下环化,制得一系列新的1,3,4-噻二唑、1,3,4- 二唑和1,2,4-均三唑衍生物.化合物的结构经元素分析、IR、1HMR和MS确证,并对其波谱性质进行了讨论.     

新型3-取代-6-(4-氯苯基)-7-(1H-1,2,4-三唑-1-基)-1',2',4'-三唑[3,4-b]-1",3",4"-噻二嗪衍生物的合成及抗菌活性

通过3-取代-4-氨基-5-巯基-1,2,4-三唑(3a～3m)和2-溴-2-(1H–1,2,4-三唑-1-基)-4′-氯代苯乙酮(2)的缩合反应,合成了13个新型3-取代-6-(4-氯苯基)-7-(1H-1,2,4-三唑-1-基)-1',2',4'-三唑[3,4-b]-1",3",4"-噻二嗪衍生物4a～4m.化合物结构经元素分析,1HNMR,IR和MS进行了表征.抗菌试验表明所合成的化合物对细菌表现出中等程度的抑制活性.     

1-(4-取代苯基)-4-苯基-5-(2-羟基苄基)氨基-1,2,3-三唑类衍生物的合成及抑菌活性

将邻羟苯基引入1,2,3-三唑结构中, 设计合成了10个1-(4-取代苯基)-4-苯基-5-取代-1,2,3-三唑类衍生物. 首先, 以对位取代的芳胺为原料, 经重氮化、叠氮化、闭环和缩合反应制得1-(4-取代苯基)-4-苯基-5-水杨醛亚胺-1,2,3-三唑类衍生物(3a~3e), 再用硼氢化钠还原制得1-(4-取代苯基)-4-苯基-5-(2-羟基苄基)氨基-1,2,3-三唑类衍生物(4a~4e). 目标化合物的结构经核磁、IR及元素分析确认. 抑菌活性测试表明, 当质量浓度为0.1 mg/L时, 除化合物3e和4e外, 所有化合物对白色念球菌的抑菌率均达95%以上, 对大肠杆菌的抑菌率达85%以上, 具有强抑菌活性, 表明该类化合物在抗菌药物开发方面有重要应用价值.     

2-[1-(1,2,4-三唑)甲基]-3-乙酰基-2,5-二取代芳基-1,3,4-噁二唑啉类化合物的合成

在冰醋酸存在下, 4-取代苯乙酮和溴素容易进行溴代反应, 得到α-溴-4-取代苯乙酮; 将其和1,2,4-三唑在丙酮中反应, 得到α-(1,2,4-三唑-1-基)-4-取代苯乙酮2; 在冰醋酸催化下, 2和4-取代苯甲酰肼1进行缩合, 得到相应酰腙衍生物3; 化合物3在乙酸酐的作用下环化生成一系列2-[1-(1,2,4-三唑)甲基]-3-乙酰基-2,5-二取代芳基-1,3,4-噁二唑啉4. 化合物4的结构经IR, 1H NMR, MS, 元素分析和单晶衍射确证.     

1,3-偶极环加成合成新型含2-苯基-1,2,3-三唑基-1,5-苯并硫氮杂(艹/卓)噁二唑并合衍生物

α,β-不饱和酮(1a～1e)与邻氨基苯硫酚反应, 得到含2-苯基-1,2,3-三唑基1,5-苯并硫氮杂(艹/卓)(2a～2e), 然后以此化合物为原料同1,3-偶极子氧化腈"现场"发生1,3-偶极环加成, 合成出一系列含2-苯基-1,2,3-三唑基的1,2,4-(口恶)二唑并合的1,5-苯并硫氮杂衍生物(3a～3j). 产物经元素分析、 IR、 1H NMR及MS加以确证.     

2-芳胺基-5-[5′-氨基-1′-(4″-氯苯基)-1′,2′,3′-三唑-4′-基]-1,3,4-噻二唑的合成~≠

1-[5’-氨基-1’-(4”-氯苯基)-1,2,3-三唑-4’-甲酰基]-4-芳基-3-氨基硫脲在浓硫酸催化下环化得到2-芳胺基-5-[5’-氨基-1’-(4”-氯苯基)-1’,2’,3’,-三唑-4’-基]-1,3,4-噻二唑2a～i,依次法合成了九个标题化合物,收率为30～74％。化合物2i的结构用X-光衍射单晶分析确证。     

Preparation,molecular structures,and characteristic properties of (E)-1-(2-furyl)- and (E)-1-(2-thienyl)-2-(3-guaiazulenyl)ethylenes and (E)-1-(3-furyl)- and (E)-1-(3-thienyl)-2-(3-guaiazulenyl)ethylenes

Wittig reactions of 2-furaldehyde (20) [and thiophene-2-carbaldehyde (21)] with (3-guaiazulenylmethyl)triphenylphosphonium bromide (19) in ethanol containing NaOEt at 25 °C for 24 h under argon give (E)-1-(2-furyl)-2-(3-guaiazulenyl)ethylene (22E) and (E)-1-(2-thienyl)-2-(3-guaiazulenyl)ethylene (23E) in 53 and 36% yields. Similarly, Wittig reactions of 3-furaldehyde (29) [and thiophene-3-carbaldehyde (30)] with 19 under the same reaction conditions as for 20 and 21 afford (E)-1-(3-furyl)-2-(3-guaiazulenyl)ethylene (31E) and (E)-1-(3-thienyl)-2-(3-guaiazulenyl)ethylene (32E) in 32 and 46% yields. Molecular structures and characteristic properties as well as preparation of the title E (i.e., one of the geometrical isomers) forms, with a view to comparative study, are reported. Moreover, reactions of those conjugated π-electron systems with TCNE (=tetracyanoethylene) in benzene [and in DMF (=N,N-dimethylformamide)] at 25 °C for 24 h under argon yield unique products, possessing interesting molecular structures, respectively, whose characteristic properties and crystal structures are documented, also.     

First row transition metal complexes of (E)-2-(2-(2-hydroxybenzylidene) hydrazinyl)-2-oxo-N-phenylacetamide complexes

Manganese(II), iron(II), cobalt(II), nickel(II), copper(II), and chromium(III) complexes of (E)-2-(2-(2-hydroxybenzylidene)hydrazinyl)-2-oxo-N-phenylacetamide were synthesized and characterized by elemental and thermal (TG and DTA) analyses, IR, UV-vis and (1)H NMR spectra as well as magnetic moment. Mononuclear complexes are obtained with 1:1 molar ratio except [Mn(HOS)(2)(H(2)O)(2)] and [Co(OS)(2)](H(2)O)(2) complexes which are obtained with 1:2 molar ratios. The IR spectra of ligand and metal complexes reveal various modes of chelation. The ligand behaves as a monobasic bidentate one and coordination occurs via the enolic oxygen atom and azomethine nitrogen atom. The ligand behaves also as a monobasic tridentate one and coordination occurs through the carbonyl oxygen atom, azomethine nitrogen atom and the hydroxyl oxygen. Moreover, the ligand behaves as a dibasic tridentate and coordination occurs via the enolic oxygen, azomethine nitrogen and the hydroxyl oxygen atoms. The electronic spectra and magnetic moment measurements reveal that all complexes possess octahedral geometry except the copper complexes possesses a square planar geometry. From the modeling studies, the bond length, bond angle, HOMO, LUMO and dipole moment had been calculated to confirm the geometry of the ligands and their investigated complexes. The thermal studies showed the type of water molecules involved in metal complexes as well as the thermal decomposition of some metal complexes. The protonation constant of the ligand and the stability constant of metal complexes were determined pH-metrically in 50% (v/v) dioxane-water mixture at 298 K and found to be consistent with Irving-Williams order. Moreover, the minimal inhibitory concentration (MIC) of these compounds against Staphylococcus aureus, Escherechia coli and Candida albicans were determined.     

Bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine

(E)-5-(2-Bromovinyl)-2'-deoxyuridine is an antiviral drug that is experimentally used for modulation of the antitumour effect of fluoropyrimidines, such as ftorafur and 5-fluorouracil. The isolation of the analyte, in the presence of 5-fluorouracil, from the matrix is performed either by means of a simple protein precipitation (plasma) or by means of a liquid-liquid extraction with ethyl acetate (urine). Following pretreatment, the analyte is analysed by reversed-phase chromatography and quantified by absorbance detection at 307 nm. The minimum detectable concentration in plasma and urine samples is ca. 6 ng/ml. The recovery after deproteination of plasma samples is 75%, while after liquid-liquid extraction of urine the recovery amounts 92%. The degree of protein binding of the analyte, measured by ultrafiltration, is found to be 97%. These data allow the bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine for pharmacokinetic studies.